BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortés J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P; monarchE Committee Members and Investigators. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 2020;38:3987-98. [PMID: 32954927 DOI: 10.1200/JCO.20.02514] [Cited by in Crossref: 75] [Cited by in F6Publishing: 23] [Article Influence: 37.5] [Reference Citation Analysis]
Number Citing Articles
1 Migliaccio I, Leo A, Galardi F, Guarducci C, Fusco GM, Benelli M, Di Leo A, Biganzoli L, Malorni L. Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer. Cancers (Basel) 2021;13:2640. [PMID: 34072070 DOI: 10.3390/cancers13112640] [Reference Citation Analysis]
2 Bartsch R. ESMO 2020: highlights in breast cancer. Memo 2021;:1-4. [PMID: 33968263 DOI: 10.1007/s12254-021-00713-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Curigliano G. CDK4/6 inhibitors for HR+HER2- early stage breast cancer - when to escalate treatment? Nat Rev Clin Oncol 2021;18:67-8. [PMID: 33235325 DOI: 10.1038/s41571-020-00453-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Reinert T, de Souza ABA, Sartori GP, Obst FM, Barrios CH. Highlights of the 17th St Gallen International Breast Cancer Conference 2021: customising local and systemic therapies. Ecancermedicalscience 2021;15:1236. [PMID: 34221119 DOI: 10.3332/ecancer.2021.1236] [Reference Citation Analysis]
5 Komforti M, Downs-Kelly E, Sapunar F, Wijayawardana SR, Gruver AM, Badve SS. Two Instrument Comparison of Reagents From a US FDA-Approved Assay for the Assessment of Ki-67 in High-Risk Early Breast Cancer. Appl Immunohistochem Mol Morphol 2022. [PMID: 35880975 DOI: 10.1097/PAI.0000000000001050] [Reference Citation Analysis]
6 Sorscher S. Biomarkers for CDK4/6 inhibitor efficacy. Breast J 2021;27:103. [PMID: 33289260 DOI: 10.1111/tbj.14127] [Reference Citation Analysis]
7 Suski JM, Braun M, Strmiska V, Sicinski P. Targeting cell-cycle machinery in cancer. Cancer Cell 2021;39:759-78. [PMID: 33891890 DOI: 10.1016/j.ccell.2021.03.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Benot-Dominguez R, Cimini A, Barone D, Giordano A, Pentimalli F. The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers? Cancers (Basel) 2022;14:2709. [PMID: 35681689 DOI: 10.3390/cancers14112709] [Reference Citation Analysis]
9 Pilewskie M, Sevilimedu V, Eroglu I, Le T, Wang R, Morrow M, Braunstein LZ. How Often Do Sentinel Lymph Node Biopsy Results Affect Adjuvant Therapy Decisions Among Postmenopausal Women with Early-Stage HR+/HER2- Breast Cancer in the Post-RxPONDER Era? Ann Surg Oncol 2022. [PMID: 35849294 DOI: 10.1245/s10434-022-12193-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ferraro E, Walsh EM, Tao JJ, Chandarlapaty S, Jhaveri K. Accelerating drug development in breast cancer: New frontiers for ER inhibition. Cancer Treat Rev 2022;109:102432. [PMID: 35839531 DOI: 10.1016/j.ctrv.2022.102432] [Reference Citation Analysis]
11 Sun R, McCaw Z, Tian L, Uno H, Hong F, Kim DH, Wei LJ. Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study. J Immunother Cancer 2021;9:e003323. [PMID: 34799398 DOI: 10.1136/jitc-2021-003323] [Reference Citation Analysis]
12 Vasan N, Cantley LC. At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy. Nat Rev Clin Oncol 2022. [PMID: 35484287 DOI: 10.1038/s41571-022-00633-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Lopez-Tarruella S, Echavarria I, Jerez Y, Herrero B, Gamez S, Martin M. How we treat HR-positive, HER2-negative early breast cancer. Future Oncol 2022. [PMID: 35094535 DOI: 10.2217/fon-2021-0668] [Reference Citation Analysis]
14 Yousuf M, Alam M, Shamsi A, Khan P, Hasan GM, Rizwanul Haque QM, Hassan MI. Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications. Int J Biol Macromol 2022;218:394-408. [PMID: 35878668 DOI: 10.1016/j.ijbiomac.2022.07.156] [Reference Citation Analysis]
15 Martin M, Hegg R, Kim SB, Schenker M, Grecea D, Garcia-Saenz JA, Papazisis K, Ouyang Q, Lacko A, Oksuzoglu B, Reeves J, Okera M, Testa L, Shimizu C, Denduluri N, Adamchuk H, Dakhil S, Wei R, Forrester T, Fernandez MM, Zimmermann A, Headley D, Johnston SRD. Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial. JAMA Oncol 2022. [PMID: 35653145 DOI: 10.1001/jamaoncol.2022.1488] [Reference Citation Analysis]
16 Hacking SM, Yakirevich E, Wang Y. From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine. Cancers (Basel) 2022;14:3469. [PMID: 35884530 DOI: 10.3390/cancers14143469] [Reference Citation Analysis]
17 Suman VJ, Du L, Hoskin T, Anurag M, Ma C, Bedrosian I, Hunt KK, Ellis MJ, Symmans WF. Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). Clin Cancer Res 2022;28:3287-95. [PMID: 35653124 DOI: 10.1158/1078-0432.CCR-22-0068] [Reference Citation Analysis]
18 Sager RA, Backe SJ, Ahanin E, Smith G, Nsouli I, Woodford MR, Bratslavsky G, Bourboulia D, Mollapour M. Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma. Nat Rev Urol 2022. [PMID: 35264774 DOI: 10.1038/s41585-022-00571-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Poggio F, Tagliamento M, Pirrone C, Soldato D, Conte B, Molinelli C, Cosso M, Fregatti P, Del Mastro L, Lambertini M. Update on the Management of Breast Cancer during Pregnancy. Cancers (Basel) 2020;12:E3616. [PMID: 33287242 DOI: 10.3390/cancers12123616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Lee JS, Yost SE, Li SM, Cui Y, Frankel PH, Yuan Y, Schmolze D, Egelston CA, Guo W, Murga M, Chang H, Bosserman L, Yuan Y. Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer. Cancers 2022;14:3159. [DOI: 10.3390/cancers14133159] [Reference Citation Analysis]
21 Rugo HS, O'Shaughnessy J, Boyle F, Toi M, Broom R, Blancas I, Gumus M, Yamashita T, Im YH, Rastogi P, Zagouri F, Song C, Campone M, San Antonio B, Shahir A, Hulstijn M, Brown J, Zimmermann A, Wei R, Johnston S, Reinisch M, Tolaney SM; monarchE Committee Members. Adjuvant Abemaciclib Combined with Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study. Ann Oncol 2022:S0923-7534(22)00383-0. [PMID: 35337972 DOI: 10.1016/j.annonc.2022.03.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
22 Guo X, Chen H, Zhou Y, Shen L, Wu S, Chen Y. Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition. Expert Opin Investig Drugs 2022;:1-12. [PMID: 35786092 DOI: 10.1080/13543784.2022.2097067] [Reference Citation Analysis]
23 Dowsett M, Nielsen TO, Rimm DL, Hayes DF. Ki67 as a Companion Diagnostic: Good or Bad News? J Clin Oncol 2022;:JCO2200581. [PMID: 35816627 DOI: 10.1200/JCO.22.00581] [Reference Citation Analysis]
24 Martelli V, Latocca MM, Ruelle T, Perachino M, Arecco L, Beshiri K, Razeti MG, Tagliamento M, Cosso M, Fregatti P, Lambertini M. Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women. Breast Cancer (Dove Med Press) 2021;13:341-51. [PMID: 34079366 DOI: 10.2147/BCTT.S274283] [Reference Citation Analysis]
25 Cescon DW, Kalinsky K, Parsons HA, Smith KL, Spears PA, Thomas A, Zhao F, DeMichele A. Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches. Front Oncol 2021;11:667397. [PMID: 35223447 DOI: 10.3389/fonc.2021.667397] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Borges VF. The Expanded Role of Ovarian Suppression for Young Women's Breast Cancer: An Era of Patient-Tailored Decision Making. J Natl Cancer Inst 2021:djab214. [PMID: 34850044 DOI: 10.1093/jnci/djab214] [Reference Citation Analysis]
27 Chandra Doval D, Mehta A, Somashekhar SP, Gunda A, Singh G, Bal A, Khare S, Prakash V Serkad C, Adinarayan M, Krishnamoorthy N, Vijay DG, Anantakrishnan R, Bhattacharyya GS, Bakre MM. The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin. Breast 2021;59:1-7. [PMID: 34098459 DOI: 10.1016/j.breast.2021.05.007] [Reference Citation Analysis]
28 Goel S, Bergholz JS, Zhao JJ. Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer 2022. [PMID: 35304604 DOI: 10.1038/s41568-022-00456-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
29 Royce M, Osgood C, Mulkey F, Bloomquist E, Pierce WF, Roy A, Kalavar S, Ghosh S, Philip R, Rizvi F, Mixter BD, Tang S, Pazdur R, Beaver JA, Amiri-Kordestani L. FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer. J Clin Oncol 2022;:JCO2102742. [PMID: 35084948 DOI: 10.1200/JCO.21.02742] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
30 Battisti NML, Joshi K, Nasser MS, Ring A. Systemic therapy for older patients with early breast cancer. Cancer Treat Rev 2021;100:102292. [PMID: 34536728 DOI: 10.1016/j.ctrv.2021.102292] [Reference Citation Analysis]
31 Chen K, Shields MD, Chauhan PS, Ramirez RJ, Harris PK, Reimers MA, Zevallos JP, Davis AA, Pellini B, Chaudhuri AA. Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors. Mol Diagn Ther 2021;25:757-74. [PMID: 34725800 DOI: 10.1007/s40291-021-00559-x] [Reference Citation Analysis]
32 Lee MK, Montagna G, Pilewskie ML, Sevilimedu V, Morrow M. Axillary Staging Is Not Justified in Postmenopausal Clinically Node-Negative Women Based on Nodal Disease Burden. Ann Surg Oncol 2022. [PMID: 35876927 DOI: 10.1245/s10434-022-12203-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Fleming GF, Pagani O, Regan MM, Walley BA, Francis PA. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 2022:S0923-7534(22)00380-5. [PMID: 35301096 DOI: 10.1016/j.annonc.2022.03.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Regan MM. Accelerating progress to innovation for patients: Trial design and risk stratification. Breast 2021:S0960-9776(21)00993-0. [PMID: 34836764 DOI: 10.1016/j.breast.2021.11.010] [Reference Citation Analysis]
35 Graff SL. Treatment of Premenopausal Women: Finding the Right-Sized Endocrine Therapy. JCO Oncol Pract 2021;:OP2100720. [PMID: 34780307 DOI: 10.1200/OP.21.00720] [Reference Citation Analysis]
36 Van Baelen K, Geukens T, Maetens M, Tjan – Heijnen V, Lord C, Linn S, Bidard F, Richard F, Yang W, Steele R, Pettitt S, Van Ongeval C, De Schepper M, Isnaldi E, Nevelsteen I, Smeets A, Punie K, Voorwerk L, Wildiers H, Floris G, Vincent-salomon A, Derksen P, Neven P, Senkus E, Sawyer E, Kok M, Desmedt C. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. Annals of Oncology 2022. [DOI: 10.1016/j.annonc.2022.05.006] [Reference Citation Analysis]
37 Kim R, Kawai A, Wakisaka M, Shimoyama M, Yasuda N, Kin T, Arihiro K. Breast cancer recurrence and survival rates in patients who underwent breast-conserving surgery under non-mechanically ventilated anesthesia. Cancer Rep (Hoboken) 2022;:e1643. [PMID: 35655440 DOI: 10.1002/cnr2.1643] [Reference Citation Analysis]
38 Cescon DW, Kalinsky K, DeMichele AM. Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer? J Clin Oncol 2022;:JCO2201026. [PMID: 35658519 DOI: 10.1200/JCO.22.01026] [Reference Citation Analysis]
39 Tateo V, Manuzzi L, Parisi C, De Giglio A, Campana D, Pantaleo MA, Lamberti G. An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances. Pharmaceuticals (Basel) 2021;14:316. [PMID: 33915954 DOI: 10.3390/ph14040316] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Nelson DR, Brown J, Morikawa A, Method M. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics. PLoS One 2022;17:e0264637. [PMID: 35213669 DOI: 10.1371/journal.pone.0264637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Chen J, Wan R, Li Q, Rao Z, Wang Y, Zhang L, Teichmann AT. Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer. Cancer Cell Int 2021;21:306. [PMID: 34112175 DOI: 10.1186/s12935-021-01999-5] [Reference Citation Analysis]
42 Li J, Jiang Z. Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification. Cancer Biol Med 2022:j. [PMID: 35765123 DOI: 10.20892/j.issn.2095-3941.2022.0277] [Reference Citation Analysis]
43 Yadav S, Giridhar KV, Leone JP, Leon-ferre RA, Ruddy KJ. A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer. Breast Cancer Management 2021;10:BMT59. [DOI: 10.2217/bmt-2021-0001] [Reference Citation Analysis]
44 Perachino M, Poggio F, Arecco L, Blondeaux E, Spinaci S, Marrocco C, Levaggi A, Lambertini M. Update on Pregnancy Following Breast Cancer Diagnosis and Treatment. Cancer J 2022;28:176-82. [PMID: 35594464 DOI: 10.1097/PPO.0000000000000599] [Reference Citation Analysis]
45 Mittendorf EA, King TA, Tolaney SM. Impact of RxPONDER and monarchE on the Surgical Management of the Axilla in Patients With Breast Cancer. J Clin Oncol 2022;:JCO2200173. [PMID: 35675571 DOI: 10.1200/JCO.22.00173] [Reference Citation Analysis]
46 Liao H, Pei W, Zhong J, Shao B, Liu X, Liu Y, Zhang J, Rugo HS, Li H. Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis. Front Pharmacol 2022;13:886954. [DOI: 10.3389/fphar.2022.886954] [Reference Citation Analysis]
47 Chen HW, Chen TW. Revisiting Adjuvant Hormone Therapy in Premenopausal Women With Breast Cancer: Escalation and De-Escalation. JCO Oncol Pract 2021;:OP2100730. [PMID: 34846915 DOI: 10.1200/OP.21.00730] [Reference Citation Analysis]
48 Paluch-shimon S, Cardoso F, Partridge A, Abulkhair O, Azim H, Bianchi-micheli G, Cardoso M, Curigliano G, Gelmon K, Gentilini O, Harbeck N, Kaufman B, Kim S, Liu Q, Merschdorf J, Poortmans P, Pruneri G, Senkus E, Sirohi B, Spanic T, Sulosaari V, Peccatori F, Pagani O. ESO-ESMO 5th International Consensus Guidelines for Breast Cancer in Young Women (BCY5). Annals of Oncology 2022. [DOI: 10.1016/j.annonc.2022.07.007] [Reference Citation Analysis]
49 Nitz UA, Gluz O, Kümmel S, Christgen M, Braun M, Aktas B, Lüdtke-Heckenkamp K, Forstbauer H, Grischke EM, Schumacher C, Darsow M, Krauss K, Nuding B, Thill M, Potenberg J, Uleer C, Warm M, Fischer HH, Malter W, Hauptmann M, Kates RE, Gräser M, Würstlein R, Shak S, Baehner F, Kreipe HH, Harbeck N; West German Study Group. Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer. J Clin Oncol 2022;:JCO2102759. [PMID: 35404683 DOI: 10.1200/JCO.21.02759] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
50 Loibl S, Furlanetto J. Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer. Breast 2021:S0960-9776(21)01014-6. [PMID: 34930649 DOI: 10.1016/j.breast.2021.12.008] [Reference Citation Analysis]
51 Bachelot T, Cottu P, Chabaud S, Dalenc F, Allouache D, Delaloge S, Jacquin JP, Grenier J, Venat Bouvet L, Jegannathen A, Campone M, Del Piano F, Debled M, Hardy-Bessard AC, Giacchetti S, Mouret-Reynier MA, Barthelemy P, Kaluzinski L, Mailliez A, Legouffe E, Sephton M, Bliss J, Canon JL, Penault-Llorca F, Lemonnier J, Cameron D, Andre F. Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. J Clin Oncol 2022;:JCO2102179. [PMID: 35605174 DOI: 10.1200/JCO.21.02179] [Reference Citation Analysis]
52 Strasser-weippl K. Breast Cancer—Essential news of current guidelines. memo 2022;15:117-20. [DOI: 10.1007/s12254-022-00799-5] [Reference Citation Analysis]
53 Sammons S, Moore H, Cushman J, Hamilton E. Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer. Expert Rev Anticancer Ther 2022. [PMID: 35737886 DOI: 10.1080/14737140.2022.2093719] [Reference Citation Analysis]
54 Mayer EL, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein HJ, Zdenkowski N, Wette V, Miller KD, Balic M, Mayer IA, Cameron D, Winer EP, Ponce Lorenzo JJ, Lake D, Pristauz-Telsnigg G, Haddad TC, Shepherd L, Iwata H, Goetz M, Cardoso F, Traina TA, Sabanathan D, Breitenstein U, Ackerl K, Metzger Filho O, Zehetner K, Solomon K, El-Abed S, Theall KP, Lu DR, Dueck A, Gnant M, DeMichele A. Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). J Clin Oncol 2022;40:449-58. [PMID: 34995105 DOI: 10.1200/JCO.21.01918] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
55 Ozaki Y, Miura S, Oki R, Morikawa T, Uchino K. Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature. Cancers (Basel) 2021;14:196. [PMID: 35008357 DOI: 10.3390/cancers14010196] [Reference Citation Analysis]
56 Ditsch N, Kolberg-Liedtke C, Friedrich M, Jackisch C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, Dall P, Fallenberg EM, Fasching PA, Fehm T, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Nitz U, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Janni W, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care (Basel) 2021;16:214-27. [PMID: 34248462 DOI: 10.1159/000516419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Kandemir EA. Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021. J Oncol Pharm Pract 2022;:10781552221112015. [PMID: 35793068 DOI: 10.1177/10781552221112015] [Reference Citation Analysis]
58 Tesch ME, Partridge AH. Treatment of Breast Cancer in Young Adults. Am Soc Clin Oncol Educ Book 2022;42:1-12. [PMID: 35580291 DOI: 10.1200/EDBK_360970] [Reference Citation Analysis]
59 Matikas A, Kotsakis A, Apostolaki S, Politaki H, Perraki M, Kalbakis K, Nikolaou M, Economopoulou P, Hatzidaki D, Georgoulias V. Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer. Br J Cancer 2022. [PMID: 35145253 DOI: 10.1038/s41416-022-01699-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
60 Torres-guzmán R, Ganado MP, Mur C, Marugan C, Baquero C, Yang Y, Zeng Y, Bian H, Du J, de Dios A, Puig O, Lallena MJ. Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation. Oncotarget 2022;13:864-75. [DOI: 10.18632/oncotarget.28249] [Reference Citation Analysis]
61 Potter DA, Herrera-Ponzanelli CA, Hinojosa D, Castillo R, Hernandez-Cruz I, Arrieta VA, Franklin MJ, Yee D. Recent advances in neoadjuvant therapy for breast cancer. Fac Rev 2021;10:2. [PMID: 33659921 DOI: 10.12703/r/10-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
62 Brown J, Scardo S, Method M, Schlauch D, Misch A, Picard S, Hamilton E, Jones S, Burris H, Spigel D. A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States. BMC Cancer 2022;22:502. [PMID: 35524219 DOI: 10.1186/s12885-022-09557-6] [Reference Citation Analysis]
63 Tarantino P, Burstein HJ, Lin NU, Krop IE, Winer EP, Schnitt SJ, Hamilton EP, Hurvitz SA, Rugo HS, Curigliano G, Tolaney SM. Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? Ann Oncol 2021:S0923-7534(21)04877-8. [PMID: 34942341 DOI: 10.1016/j.annonc.2021.12.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Kurozumi S, Kaira K, Matsumoto H, Kurosumi M, Yokobori T, Kanai Y, Sekine C, Honda C, Katayama A, Furuya M, Shiino S, Makiguchi T, Mongan NP, Rakha EA, Oyama T, Fujii T, Shirabe K, Horiguchi J. Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer. Sci Rep 2022;12:2742. [PMID: 35177712 DOI: 10.1038/s41598-022-06615-8] [Reference Citation Analysis]
65 Hou Y, Peng Y, Li Z. Update on prognostic and predictive biomarkers of breast cancer. Semin Diagn Pathol 2022:S0740-2570(22)00053-3. [PMID: 35752515 DOI: 10.1053/j.semdp.2022.06.015] [Reference Citation Analysis]
66 Watson NW, Wander SA, Shatzel JJ, Al-Samkari H. Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer. Cancer 2022. [PMID: 35767226 DOI: 10.1002/cncr.34367] [Reference Citation Analysis]
67 Mavratzas A, Marmé F. Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice? Breast Care (Basel) 2021;16:115-28. [PMID: 34012366 DOI: 10.1159/000514561] [Reference Citation Analysis]
68 Weiss A, King C, Grossmith S, Portnow L, Raza S, Nakhlis F, Dominici L, Barbie T, Minami C, Nimbkar S, Rhei E, Mittendorf EA, King TA. How Often Does Retrieval of a Clipped Lymph Node Change Adjuvant Therapy Recommendations? A Prospective, Consecutive, Patient Cohort Study. Ann Surg Oncol 2022. [PMID: 35041097 DOI: 10.1245/s10434-022-11324-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
69 Franzoi MA, Lambertini M, Ceppi M, Bruzzone M, de Azambuja E. Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients. Breast Cancer Res Treat. [DOI: 10.1007/s10549-022-06525-3] [Reference Citation Analysis]
70 Rubovszky G, Kocsis J, Boér K, Chilingirova N, Dank M, Kahán Z, Kaidarova D, Kövér E, Krakovská BV, Máhr K, Mriňáková B, Pikó B, Božović-spasojević I, Horváth Z. Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. Pathol Oncol Res 2022;28:1610383. [DOI: 10.3389/pore.2022.1610383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
71 Ben-Dror J, Shalamov M, Sonnenblick A. The History of Early Breast Cancer Treatment. Genes (Basel) 2022;13:960. [PMID: 35741721 DOI: 10.3390/genes13060960] [Reference Citation Analysis]
72 Yu J, Li NL. Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report. World J Clin Cases 2022; 10(17): 5923-5928 [DOI: 10.12998/wjcc.v10.i17.5923] [Reference Citation Analysis]
73 Thomssen C, Fehm TN, Stickeler E, Fasching PA, Janni W, Kolberg-liedtke C, Kolberg H, Lüftner D, Müller V, Schütz F, Belleville E, Bader S, Untch M, Welslau M, Thill M, Hartkopf AD, Tesch H, Ditsch N, Lux MP, Wöckel A, Aktas B, Schneeweiss A, Würstlein R. Update Breast Cancer 2021 Part 4 – Prevention and Early Stages. Geburtshilfe Frauenheilkd 2022;82:206-14. [DOI: 10.1055/a-1724-9639] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Andrahennadi S, Sami A, Manna M, Pauls M, Ahmed S. Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer. Curr Oncol 2021;28:1803-22. [PMID: 34064867 DOI: 10.3390/curroncol28030168] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
75 Fassl A, Geng Y, Sicinski P. CDK4 and CDK6 kinases: From basic science to cancer therapy. Science 2022;375:eabc1495. [PMID: 35025636 DOI: 10.1126/science.abc1495] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
76 Wilson N, Ironside A, Diana A, Oikonomidou O. Lobular Breast Cancer: A Review. Front Oncol 2020;10:591399. [PMID: 33520704 DOI: 10.3389/fonc.2020.591399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Sheffield KM, Peachey JR, Method M, Grimes BR, Brown J, Saverno K, Sugihara T, Cui ZL, Lee KT. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. Future Oncol 2022. [PMID: 35611679 DOI: 10.2217/fon-2022-0310] [Reference Citation Analysis]
78 Stickeler E, Aktas B, Behrens A, Belleville E, Ditsch N, Fasching PA, Fehm TN, Hartkopf AD, Jackisch C, Janni W, Kolberg-Liedtke C, Kolberg HC, Lüftner D, Lux MP, Müller V, Schneeweiss A, Schütz F, Schulmeyer CE, Tesch H, Thomssen C, Uleer C, Untch M, Welslau M, Wöckel A, Wurmthaler LA, Würstlein R, Thill M. Update Breast Cancer 2021 Part 1 - Prevention and Early Stages. Geburtshilfe Frauenheilkd 2021;81:526-38. [PMID: 34035547 DOI: 10.1055/a-1464-0953] [Reference Citation Analysis]
79 Elfgen C, Bjelic-Radisic V. Targeted Therapy in HR+ HER2- Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options. Cancers (Basel) 2021;13:5994. [PMID: 34885105 DOI: 10.3390/cancers13235994] [Reference Citation Analysis]
80 Tung N, Garber JE. PARP inhibition in breast cancer: progress made and future hopes. NPJ Breast Cancer 2022;8:47. [PMID: 35396508 DOI: 10.1038/s41523-022-00411-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Antonarelli G, Valenza C, Mayer EL, Loibl S, Curigliano G. Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67? The Lancet Oncology 2022;23:325-8. [DOI: 10.1016/s1470-2045(21)00756-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Freedman RA, Graff SL, Somerfield MR, Telli ML, Wolff AC, Giordano SH. Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncol Pract 2022;:OP2200140. [PMID: 35377771 DOI: 10.1200/OP.22.00140] [Reference Citation Analysis]
83 McGuinness JE, Ro V, Mutasa S, Pan S, Hu J, Trivedi MS, Accordino MK, Kalinsky K, Hershman DL, Ha RS, Crew KD. Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer. Breast Cancer Res Treat 2022. [PMID: 35575954 DOI: 10.1007/s10549-022-06614-3] [Reference Citation Analysis]
84 Morganti S, Marra A, Crimini E, D’amico P, Zagami P, Curigliano G. Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation? Breast Cancer Res Treat. [DOI: 10.1007/s10549-022-06535-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Abdel-razeq H, Sharaf B, Almasri R, Abdel-razeq R, Tamimi F, Khader O, Salama O, Abunasser M, Edaily S, Abdulelah H. Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data. CMAR 2022;Volume 14:1033-41. [DOI: 10.2147/cmar.s353584] [Reference Citation Analysis]
86 Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, Bliss JM, Mayer IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, Hernando Fernández de Aránguiz B, Haddad TC, Perelló A, Bellet M, Fohler H, Metzger Filho O, Jallitsch-Halper A, Solomon K, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL; PALLAS groups and investigators. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol 2021;:JCO2102554. [PMID: 34874182 DOI: 10.1200/JCO.21.02554] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
87 Morita M, Shimomura A, Tokuda E, Horimoto Y, Kawamura Y, Ishizuka Y, Sekine K, Obayashi S, Kojima Y, Uemura Y, Higuchi T. Is adjuvant chemotherapy necessary in older patients with breast cancer? Breast Cancer 2022. [PMID: 35032302 DOI: 10.1007/s12282-021-01329-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Ring A, Spataro M, Wicki A, Aceto N. Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer. Front Cell Dev Biol 2022;10:929893. [DOI: 10.3389/fcell.2022.929893] [Reference Citation Analysis]
89 Chan W, Martinez-cannon BA, Chavarri-guerra Y, Kwong GW. Perspectives on Geriatric Oncology Research Presented at the 2021 San Antonio Breast Cancer Symposium: A Young International Society of Geriatric Oncology Report. Journal of Geriatric Oncology 2022. [DOI: 10.1016/j.jgo.2022.03.006] [Reference Citation Analysis]
90 Lux MP, Schneeweiss A, Hartkopf AD, Müller V, Janni W, Belleville E, Stickeler E, Thill M, Fasching PA, Kolberg HC, Untch M, Harbeck N, Wöckel A, Thomssen C, Schulmeyer CE, Welslau M, Overkamp F, Schütz F, Lüftner D, Ditsch N. Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients. Geburtshilfe Frauenheilkd 2021;81:469-80. [PMID: 33867564 DOI: 10.1055/a-1397-7170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Delaloge S, Dureau S, D'Hondt V, Desmoulins I, Heudel PE, Duhoux FP, Levy C, Lerebours F, Mouret-Reynier MA, Dalenc F, Frenel JS, Jouannaud C, Venat-Bouvet L, Nguyen S, Callens C, Gentien D, Rapinat A, Manduzio H, Vincent-Salomon A, Lemonnier J, Cottu P; French Breast cancer Intergroup Unicancer-UCBG. Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. Eur J Cancer 2022:S0959-8049(22)00035-1. [PMID: 35337692 DOI: 10.1016/j.ejca.2022.01.014] [Reference Citation Analysis]
92 Harbeck N, Rastogi P, Shahir A, Johnston S, O'Shaughnessy J. Letter to the Editor for 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study'. Ann Oncol 2021:S0923-7534(21)04551-8. [PMID: 34756989 DOI: 10.1016/j.annonc.2021.10.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
93 Beusterien K, Maculaitis MC, Hallissey B, Gaschler MM, Smith ML, Law EH. Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment. Patient Prefer Adherence 2021;15:611-23. [PMID: 33776424 DOI: 10.2147/PPA.S298670] [Reference Citation Analysis]
94 Dannehl D, Volmer LL, Weiss M, Matovina S, Grischke E, Oberlechner E, Seller A, Walter CB, Hahn M, Engler T, Brucker SY, Hartkopf AD. Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center. JPM 2022;12:382. [DOI: 10.3390/jpm12030382] [Reference Citation Analysis]
95 Spring L, Matikas A, Bardia A, Foukakis T. Adjuvant abemaciclib for high-risk breast cancer: the story continues. Ann Oncol 2021;32:1457-9. [PMID: 34815015 DOI: 10.1016/j.annonc.2021.10.214] [Reference Citation Analysis]
96 Wander SA, O'Brien N, Litchfield LM, O'Dea D, Morato Guimaraes C, Slamon DJ, Goel S. Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib. Oncologist 2022:oyac138. [PMID: 35917168 DOI: 10.1093/oncolo/oyac138] [Reference Citation Analysis]
97 Hicks D, O'Regan RM. Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition. J Clin Oncol 2022;:JCO2102850. [PMID: 35201844 DOI: 10.1200/JCO.21.02850] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Kim R, Kin T. Clinical Perspectives in Addressing Unsolved Issues in (Neo)Adjuvant Therapy for Primary Breast Cancer. Cancers (Basel) 2021;13:926. [PMID: 33672204 DOI: 10.3390/cancers13040926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Aristei C, Bölükbaşı Y, Kaidar-Person O, Pfeffer R, Arenas M, Boersma LJ, Ciabattoni A, Coles CE, Franco P, Krengli M, Leonardi MC, Marazzi F, Masiello V, Meattini I, Montero A, Offersen B, Trigo ML, Bourgier C, Genovesi D, Kouloulias V, Morganti AG, Meduri B, Pasinetti N, Pedretti S, Perrucci E, Rivera S, Tombolini V, Vidali C, Valentini V, Poortmans P. Ways to improve breast cancer patients' management and clinical outcome: The 2020 Assisi Think Tank Meeting. Crit Rev Oncol Hematol 2022;:103774. [PMID: 35917884 DOI: 10.1016/j.critrevonc.2022.103774] [Reference Citation Analysis]
100 George MA, Qureshi S, Omene C, Toppmeyer DL, Ganesan S. Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer. Front Oncol 2021;11:693104. [PMID: 34327137 DOI: 10.3389/fonc.2021.693104] [Reference Citation Analysis]
101 Fehm TN, Stickeler E, Fasching PA, Janni W, Kolberg-Liedtke C, Kolberg HC, Lüftner D, Müller V, Schütz F, Thomssen C, Belleville E, Behrens A, Bader S, Untch M, Welslau M, Würstlein R, Thill M, Krug D, Hartkopf AD. Update Breast Cancer 2021 Part 3 - Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. Geburtshilfe Frauenheilkd 2021;81:654-65. [PMID: 34168379 DOI: 10.1055/a-1487-7642] [Reference Citation Analysis]
102 Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F. Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System. Cancers (Basel) 2021;13:1758. [PMID: 33917020 DOI: 10.3390/cancers13081758] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Yang Y, Li J, Liu Y, Zhong Y, Ren W, Tan Y, He Z, Li C, Ouyang J, Hu Q, Yu Y, Yao H. Magnetic resonance imaging radiomics signatures for predicting endocrine resistance in hormone receptor-positive non-metastatic breast cancer. Breast 2021;60:90-7. [PMID: 34536884 DOI: 10.1016/j.breast.2021.09.005] [Reference Citation Analysis]
104 Varnier R, Sajous C, de Talhouet S, Smentek C, Péron J, You B, Reverdy T, Freyer G. Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives. Cancers (Basel) 2021;13:4840. [PMID: 34638325 DOI: 10.3390/cancers13194840] [Reference Citation Analysis]
105 Duarte SAC, de Azevedo DSP, Sarmento TTRM, Sousa MVV. Palbociclib in breast cancer neoadjuvant setting. Autops Case Rep 2021;11:e2021309. [PMID: 34458177 DOI: 10.4322/acr.2021.309] [Reference Citation Analysis]
106 Kirwan CC, Blower EL. Contemporary breast cancer treatment-associated thrombosis. Thrombosis Research 2022;213:S8-S15. [DOI: 10.1016/j.thromres.2021.12.025] [Reference Citation Analysis]
107 Moreau-Bachelard C, Campion L, Robert M, Kerdraon O, Renaudeau C, Aumont M, Classe JM, Campone M, Frénel JS. Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients. Cancers (Basel) 2020;12:E3725. [PMID: 33322473 DOI: 10.3390/cancers12123725] [Reference Citation Analysis]
108 Gandhi S, Brackstone M, Hong NJL, Grenier D, Donovan E, Lu F, Skarpathiotakis M, Lee J, Boileau J, Perera F, Simmons C, Joy AA, Tran WT, Tyono I, Van Massop A, Khalfan S; The Canadian National Neoadjuvant Breast Cancer Consortium. A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles. Breast Cancer Res Treat. [DOI: 10.1007/s10549-022-06522-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]